BriaCell Therapeutics - Warrants (24/02/2025) Common Stock

As of the most recent data (April 2026), BCTXW shows a common stock of $120M. That compares with $94M in the prior-year period — up 24.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BCTXW's common stock is now $120M (was $94M) — a 24.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether BriaCell Therapeutics - Warrants (24/02/2025) is outperforming or lagging.

Tracking BCTXW's common stock over time shows whether BriaCell Therapeutics - Warrants (24/02/2025) is scaling, shrinking, or reshaping that part of the business. The current reading is $120M That compares with $94M in the prior-year period — up 24.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this common stock page, Stockcircle has BriaCell Therapeutics - Warrants (24/02/2025)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $120M) with ownership activity and broader fundamentals.

BriaCell Therapeutics - Warrants (24/02/2025)'s common stock is $120M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.